Spy1 is a member of the Speedy/Ringo family, which regulates cell proliferation and survival. Spy1 has been demonstrated to promote the cell-cycle progress through p27(Kip1) degradation. Previous investigations have suggested cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM) is a primary factor for minimal residual disease (MRD) leading to relapse after chemotherapy. However, the precise mechanism remains elusive. In this study, we used MM cell lines to determine whether Spy1 plays a role in CAM-DR. We demonstrated that adhesion of MM cells to fibronectin (FN) decreased Spy1 expression. Overexpression of Spy1 did not affect MM cells adhesion to FN, but did reverse the doxorubicin- or mitoxantrone-induced CAM-DR phenotype. Spy1 protein level was also correlated with reciprocal up-regulation of p27(Kip1) when RPMI 8226 cells bound FN. Spy1 overexpression promoted p27(Kip1) phosphorylation at T187, then induced the p27(Kip1) degradation in the adhesion model. In addition, increasing p27(Kip1) level or disturbing p27(Kip1) phosphorylation at T187 abolished the CAM-DR reversion when Spy1 was overexpressed. Collectively, our data suggest that Spy1 plays an important role in CAM-DR, which depends on the function of p27(Kip1). Our findings provide a rational framework for further development of Spy1 as a novel target for MM therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12185-013-1435-4 | DOI Listing |
NPJ Precis Oncol
September 2024
Department of Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Breast Cancer Res
June 2024
Department of Biomedical Sciences, University of Windsor, Windsor, ON, N9B 3P4, Canada.
Background: The cell cycle of mammary stem cells must be tightly regulated to ensure normal homeostasis of the mammary gland to prevent abnormal proliferation and susceptibility to tumorigenesis. The atypical cell cycle regulator, Spy1 can override cell cycle checkpoints, including those activated by the tumour suppressor p53 which mediates mammary stem cell homeostasis. Spy1 has also been shown to promote expansion of select stem cell populations in other developmental systems.
View Article and Find Full Text PDFCancer Diagn Progn
May 2024
Department of Molecular Biology and Genetics, Faculty of Science, Mugla Sitki Kocman University, Mugla, Turkey.
Background/aim: Cyclin-dependent kinases (CDKs) are proteins that require the binding of regulatory subunits called cyclins and play a key role in cell cycle progression and activation. CDKs play a key role in carcinogenesis of many solid malignancies, and inhibition of these proteins has produced anti-cancer effects demonstrated in preclinical studies. This narrative review was conducted to develop a hypothetical approach to determine whether Speedy/RINGO, a protein associated with CDK2, could be a possible predictive factor in breast cancer patients treated with a CDK4/6 inhibitor.
View Article and Find Full Text PDFiScience
August 2023
Key Laboratory of Laboratory Medical Diagnostics Designated by the Ministry of Education, School of Laboratory Medicine, Chongqing Medical University, Chongqing, China.
Vaccination is an effective means of preventing pneumococcal disease and SPY1 is a live attenuated pneumococcal vaccine we obtained earlier. We found IL-27 and its specific receptor (WSX-1) were increased in SPY1 vaccinated mice. Bacterial clearance and survival rates were decreased in SPY1 vaccinated IL-27Rα mice.
View Article and Find Full Text PDFBreast Cancer Res
May 2023
Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Patients with TNBC are primarily treated with neoadjuvant chemotherapy (NAC). The response to NAC is prognostic, with reductions in overall survival and disease-free survival rates in those patients who do not achieve a pathological complete response (pCR).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!